Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Up to half of all patients with clinical features of heart failure are found to have normal heart pumping function. Recently the investigators have shown that a drug called perhexiline markedly improved exercise capacity and symptoms in patients with heart failure associated with impaired cardiac pump function. In this proposal the investigators will assess whether perhexiline has beneficial effects in patients with heart failure and a normal heart pumping function.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aberdeen
• Treatments: Perhexiline

Criteria

Inclusion Criteria:

• HFpEF will be defined as:

• Clinical features consistent with heart failure

• LVEF ≥ 50%, with no evidence of significant valvular disease

• No hypertrophic cardiomyopathy, and no evidence of pericardial constriction

• Peak VO2 < 80% predicted, with RER>1 and with a pattern of gas exchange on metabolic exercise testing indicating a cardiac cause for limitation)

• Patients recruited will be in sinus rhythm

Exclusion Criteria:

• BMI >35

• Objective evidence of lung disease on formal lung function testing

• Reversible myocardial ischaemia on contrast-enhanced myocardial stress Echocardiography, and no evidence of exercise-induced mitral regurgitation (>2+)

• Impaired hepatic function; known hypersensitivity to perhexiline